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A
 
BSTRACT
 
Recent large-scale sequencing of the human genome
has facilitated novel gene discovery. A novel gene,
ML-1 (interleukin (IL)-17F), was identified from a human
expressed sequence tag (EST) sequence, a genomic
DNA clone and T cell cDNA sequences. It was found
that ML-1 shares significant sequence identity and
functional similarity with the gene encoding IL-17A,
but a distinct functional property for ML-1 has been
demonstrated. While limited information is currently
available, recent functional studies have suggested
that ML-1 (IL-17F) is a multifunctional protein with a
wide tissue expression pattern. In particular, the potent
proinflammatory action of ML-1 (IL-17F) identified
thus far, together with its association with asthma,
suggests that ML-1 (IL-17F) may have a significant role
in the regulation of airway inflammatory processes.
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I
 
NTRODUCTION
 
The homeostasis and expression of various inflammatory
diseases involve highly interactive cytokine and chemo-
kine networks. It is believed that dysregulation of the
cytokine network contributes to the expression of inflam-
matory airway diseases, such as bronchial asthma,
chronic obstructive pulmonary disease (COPD) and
bacterial pneumonia. Understanding of the complexity
of the cytokine network, together with identification of
relevant novel genes, would help to uncover the molec-
ular mechanisms of inflammatory diseases. The avail-
ability of human genome sequences and bioinformatics
tools has facilitated the gene discovery processes and
the newly identified gene can be integrated in the
pursuit of the molecular mechanisms leading to various
diseases.
Interleukin (IL)-17A is a CD4
 
+
 
 T cell-derived cytokine
and human IL-17A exists as glycosylated 20–30 kDa
homodimers. Interleukin-17A was initially recognized for
its similarity to a sequence belonging to 
 
Herpesvirus
saimiri
 
, but it had little relatedness to any other known
cytokines or other mammalian proteins.
 
1,2
 
 Recent cloning
and sequencing studies have demonstrated a family of
IL-17A-related genes with potential proinflammatory
functions.
 
3–6
 
 Recently, we and others have independently
discovered a novel cytokine, ML-1
 
7
 
 (or IL-17F
 
8,9
 
), belong-
ing to the IL-17 gene family, but its function and signal-
ing pathways remain to be defined. As part of our
ongoing molecular genetic studies of complex diseases,
the coding region sequence of ML-1 was initially identi-
fied from a human genomic DNA clone by the use of bio-
informatics tools and sequencing. In the present review,
the structural and functional characteristics of this novel
cytokine gene and the initial evidence for its involvement
in airway inflammatory disease are summarized.
 
S
 
TRUCTURAL
 
 
 
ANALYSIS
 
 
 
OF
 
 ML-1 (IL-17F) 
 
GENE
 
 
 
AND
 
 
 
PROTEIN
 
As part of a positional cloning study of a region on
chromosome 6p12 for susceptibility gene discovery for
an inherited disease, the coding region sequence of
ML-1 (IL-17F) with homology to human IL-17A was
identified from a genomic DNA clone using a GenScan
prediction program (http://www.genes.mit.edu/GEN-
SCAN.html). Reverse transcription–polymerase chain
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reaction (RT-PCR) and sequencing analysis of human
allergen-specific T cells confirmed the predicted sequence
and the splicing sites between the exons. A 947 bp full-
length cDNA was obtained using both 5
 
′
 
- and 3
 
′
 
-rapid
amplification of cDNA ends (RACE), demonstrating a
transcription start site 346 bp upstream of the start
codon and a poly(A) sequence 271 bp 3
 
′
 
 to the stop
codon. Basic local alignment search tool (BLAST) analy-
sis shows a significant degree of homology between the
second exon of the 
 
ML-1
 
 gene and the third exon of
 
IL-17A
 
. It is of interest to note that the 
 
IL-17
 
 gene is
localized on the same genomic DNA clone approxi-
mately 50 kb telemeric to the 
 
ML-1
 
 gene and that both
genes are in a tail-to-tail orientation, suggesting a
potential gene duplication event.
Alignment of the predicted amino acid sequence of
ML-1 with sequences of IL-17A and the other members
of the IL-17 family reveals the highest overall amino acid
sequence homology (70%) between ML-1 and IL-17A,
whereas there is only 20% amino acid identity between
ML-1 and the other family members.
 
4–6
 
 The alignment
shows several conserved amino acids, including a tryp-
tophan and four cysteine residues. The four cysteines in
the C-terminal half of the proteins have been shown to
form a cystine knot in the crystal structure.
 
9
 
 This cystine
knot is similar to a common structural motif seen in
growth factors, such as bone morphogenetic proteins,
transforming growth factor (TGF)-
 
β
 
, nerve growth factor
and platelet-derived growth factor. In addition, IL-17F
is  believed to form disulfide-bonded homodimers,
 
9
 
whereas other members of the IL-17 family are expressed
as tightly associated dimers.
 
ML-1
 
 (
 
IL-17F
 
) 
 
GENE
 
 
 
EXPRESSION
 
While the expression of 
 
ML-1
 
 (
 
IL-17F
 
) is seen in various
cell types and human tissues, IL-17F, like IL-17A, is
produced primarily in activated T-cells. Interleukin-17B,
IL-17C, IL-17D and IL-17E are expressed in a wide
variety of tissues.
 
4–6
 
 Interestingly, ML-1 expression in
liver, lung, ovary and fetal liver is unique when com-
pared with IL-17A. In addition, although the expression
of ML-1 was not detected in unstimulated cells, with the
exception of cord blood-derived mast cells, increased
ML-1 expression was clearly evident in different cell types
after activation.
 
7
 
 Those cell types included ragweed
allergen-stimulated peripheral blood mononuclear cells
(PBMC), allergen-specific T cell clones with different
cytokine phenotypes (Th0, Th1 and Th2), activated
basophils and activated mast cells. In addition, expres-
sion of ML-1 was found in activated CD4
 
+
 
 T cells, but
not CD8
 
+
 
 and monocytes.
 
7
 
 In contrast, 
 
IL-17A
 
 gene
expression was found in only activated CD4
 
+
 
 T cells and
PBMC.
Analyses of gene expression in bronchoalveolar
lavage (BAL) cells from asthmatic subjects challenged
with allergen or saline control shows that whereas no
detectable expression of ML-1 was seen in the BAL from
saline-challenged sites, 
 
ML-1
 
 gene expression was clearly
demonstrated in BAL from allergen-challenged sites of all
four study subjects.
 
7
 
 In contrast, no IL-17A transcripts
were detected in the BAL of subjects challenged with
allergen. These findings suggest the distribution of ML-1
is much wider than that of IL-17A, suggesting that ML-1
has more biological functions.
 
F
 
UNCTION
 
 
 
OF
 
 ML-1 (IL-17F) 
 
IN
 
 
 
VITRO
 
Human ML-1 has pleiotrophic biological activities (see
Table 1 for a summary of currently known biological
activity). It is able to induce IL-6 and IL-8 in normal
human bronchial epithelial cells (NHBE) and human
umbilical vein endothelial cells (HUVEC) in a dose- and
time- dependent manner.
 
7
 
 ML-1 and IL-17A show similar
potency in the induction of IL-6 and IL-8, suggesting that
ML-1 is also involved in neutrophil recruitment into the
airway.
 
7
 
 In addition, IL-17F induces IL-8 in fibroblast.
 
9
 
The level of IL-8 is increased in inflammatory airway
diseases, such as bronchial asthma, COPD and cystic
fibrosis.
 
10–12
 
 Neutrophil recruitment into the airway is
regulated through the chemokine network. There is a
strong correlation between the level of IL-8 and the
increase in neutrophil numbers. Administration of anti-
IL-8 monoclonal antibody results in a reduction of
neutrophil chemotaxis in patients with COPD and cystic
fibrosis.
 
12
 
 In addition, bronchial epithelial cells and
vascular endothelial cells are important cell sources of
IL-8 and may thereby control neutrophil influx in the
airway. Therefore, IL-8 release in these cell types may
play a crucial role in modulating neutrophil-associated
airway inflammation.
Although IL-17A and ML-1 induce IL-6 and IL-8
expression, IL-17A fails to induce intercellular adhesion
molecule-1 (ICAM-1) expression in NHBE.
 
7
 
 In compari-
son, ML-1 markedly induced ICAM-1 expression.
 
7
 
 It has
been shown that ICAM-1 expression is increased in bron-
chial asthma.
 
13
 
 In particular, a high level of ICAM-1
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expression, along with inflammatory cell infiltration, has
been demonstrated in bronchial biopsies from both
stable asthmatics and subjects after allergen chal-
lenge.
 
13,14
 
 Moreover, allergen challenge upregulated
ICAM-1 expression in airway epithelium, correlating with
eosinophil infiltration. It is of interest to note that ML-1
induces C-X-C chemokines, but not C-C chemokines,
such as eotaxin and RANTES,
 
7
 
 which are potent chemo-
attractants for eosinophils, suggesting a selective role of
ML-1 in neutrophil recruitment and activation. These
findings suggest that ML-1 may be involved in the expres-
sion of airway inflammation by, at least in part, facilitat-
ing leukocyte recruitment and activation via the induction
of IL-6, IL-8 and ICAM-1. Moreover, in our recent unpub-
lished study, an additive effect on the induction of IL-6
and IL-8 has been observed when cells are treated with
ML-1 (IL-17F) in combination with either Th2 cytokines
(IL-4 and IL-13) or Th1 cytokine (interferon (IFN)-
 
γ
 
;
M Kawaguchi 
 
et al.
 
, unpubl. obs., 1999).
In other studies, IL-17F has been shown to be able
to induce the expression of TGF-
 
β
 
, monocyte chemo-
attractant protein (MCP)-1 and IL-2 in HUVEC and inhib-
its endothelial cell angiogenesis, but has no effect on
hematopoiesis.
 
8
 
 These findings suggest that IL-17F would
play a possible role in cancer immunotherapy by inhibit-
ing the generation of tumor vascular supply. Interleukin-
17F also induces significant cartilage matrix synthesis,
inhibits new cartilage matrix synthesis in a dose-
dependent manner and IL-6 production in articular
cartilage suggests that IL-17F may be able to promote
skeletal tissue destruction.
 
9
 
ML-1 (IL-17)-
 
INDUCED
 
 
 
SIGNALING
 
The bronchial epithelial cells and endothelial cells are
exposed to numerous environmental stimuli that can
activate intracellular signaling cascades, leading to
altered gene expression and to a wide range of responses,
such as cytokine expression, proliferation and apoptosis.
The mitogen-activated protein kinase (MAPK) family of
protein kinases is likely to be central to these processes
because it is known to regulate intracellular signal trans-
duction in response to many agonists, including growth
factors, cytokines, hormones, oxidants and environ-
mental stress factors.
 
15
 
 Mitogen-activated protein kinase
signaling pathways are highly conserved and control a
diverse range of cellular functions in organisms, ranging
from yeast to humans. In mammals, particularly, MAPK
signaling pathways have been implicated in the control
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of cell proliferation, differentiation and apoptosis.
 
16
 
 Of
the five MAPK cascades identified to date, three have
been well characterized. These comprise: (i) the extra-
cellular regulated kinases (ERK) 1 and 2 (also known as
MAPK 1/2); (ii) the c-Jun NH2-terminal kinases (JNK) 1,
2 and 3 (also known as stress-activated protein kinases
(SAPK): SAPK1a, SAPK1b and SAPK1c); and (iii) the p38
MAPK 
 
α
 
, 
 
β
 
, 
 
γ
 
 and 
 
δ
 
 isoforms (also known as SAPK2a,
SAPK2b, SAPK3/ERK6 and SAPK4).
 
16
 
 More recent
additions include ERK3, ERK4 and ERK5/big mitogen-
activated kinase (BMK)/SAPK5.
 
17
 
 These are grouped
according to their sequence homology, specificity
towards upstream activators and different responses to
stimuli.
ML-1-induced phosphorylation of ERK1/2 reached a
maximum at 20 and 10 min in NHBE and HUVEC,
respectively, and returned to baseline levels by 60 min.
 
18
 
In contrast, no activation of p38 and JNK kinases was
seen at any time point, even after a 4 h stimulation of
cells with ML-1. In addition, preincubation of cells with
the MEK inhibitor PD98059 diminished the activation of
ERK1/2 in both NHBE and HUVEC and preincubation
with Me
 
2
 
SO did not affect the phosphorylation of
ERK1/2.
 
18
 
 We next asked whether the activation of
ERK1/2 was necessary for the stimulation of IL-6 and IL-8
production in both cell types. PD98059 inhibited, in a
dose-dependent manner, the production of both IL-6
and IL-8, whereas pretreatment of cells with Me
 
2
 
SO did
not affect cytokine protein release in both NHBE and
HUVEC.
 
18
 
 Decreased levels of gene expression for both
IL-6 and IL-8 were noted in PD98059-treated, but not in
vehicle-treated, cells, suggesting that the inhibitory effect
was at the level of transcription. This inhibitory effect of
PD98059 was further confirmed by the use of an addi-
tional inhibitor, U0126.
Mitogen-activated protein kinases are known to play a
central role in airway epithelial activation in response to
various stimuli, such as tumor necrosis factor-
 
α
 
, IL-1,
diesel exhaust particles,and influenza virus infection.
 
19
 
In addition, MAPK, including ERK1/2, are involved in
cytokine signaling in HUVEC.
 
20
 
 In our study,
 
18
 
 the
involvement of ERK kinase, but not p38 or JNK, in ML-1-
induced IL-6 and IL-8 production was demonstrated
using primary bronchial epithelial cells and endothelial
cells. Interestingly, previous data showed that ERK1/2,
but not p38 or JNK, may play an important role in
cytokine release in NHBE,
 
21
 
 although all three members
of the MAPK family are involved in cytokine expression.
Indeed, IL-17A also activates only ERK1/2 kinase in
NHBE.
 
22
 
 It is noted, however, that induction of both IL-6
and IL-8 is not completely inhibited by the ERK1/2 kinase
inhibitors PD98059 and U0126, suggesting that addi-
tional signaling pathways are involved in the induction of
these cytokines by ML-1 in these cell types.
To date, the receptor for ML-1 has not been dis-
covered. The receptor for IL-17A (IL-17R) is a single-pass
transmembrane protein of approximately 130 kDa.
 
23
 
 To
assess whether ML-1 interacts with IL-17 receptor, com-
petitive inhibition experiments were performed by meas-
uring the level of ML-1-induced 
 
ICAM-1
 
 gene expression
in the presence of varying concentrations of IL-17A. At
100 ng/mL, ML-1 markedly induced ICAM-1 expression
and the level of gene expression was not inhibited by the
inclusion of IL-17A in the culture, even at a 20-fold
higher dose (2000 ng/mL).
 
7
 
 These differential biological
effects between ML-1 and IL-17A suggest that these two
cytokines may signal via different cell surface receptors.
The downstream signaling pathway of ML-1 (IL-17F) is
also unclear. Interleukin-17A is known to activate tran-
scription factor nuclear factor (NF)-
 
κ
 
B in chondrocytes
and intestinal epithelial cells.
 
24,25
 
 Because of high homol-
ogy between IL-17A and ML-1, it is possible that ML-1 is
able to activate NF-
 
κ
 
B in the downstream signaling
pathway of ML-1. Further work is needed to uncover the
signaling pathways, including the nature of the putative
ML-1 receptor.
 
F
 
UNCTION
 
 
 
OF
 
 ML-1 (IL-17F) 
 
IN
 
 VIVO
In addition to eosinophils, it has been reported that
neutrophil accumulation into the airway is also a feature
of bronchial asthma.26 After allergen challenge, neutro-
phil infiltration was seen in the airways of patients with
severe asthma.10,27 The number of CD4+ T cells is also
increased in parallel with the number of neutrophils in
the airway of patients with COPD and bronchiecta-
sis.28,29 Furthermore, specific inhibition of CD4+ T cells,
either with a CD4 antibody or an IL-2 receptor antibody,
prevents allergen-induced recruitment of both eosino-
phils and neutrophils in animal models.30,31 However,
little is known about how CD4+ T cells induce neutrophil
accumulation into the airway. Based on our current and
previous data, it is suggested that ML-1 is the key
regulator for T cell-mediated bronchial neutrophilia.7
Indeed, using the adenoviral gene transfer strategy, it
has been suggested that the transduced IL-17F expres-
sion leads to an increased number of BAL neutrophils.32
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Of interest is the finding that lung tissues from transduced
mice show substantial increases in the levels of inflam-
matory cytokines and chemokines, including IL-6, IFN-γ,
inflammatory protein 10 and monokine induced by
IFN-γ.32 When combined with available in vitro data,
a working hypothesis can be formulated to suggest the
potential role of ML-1 (IL-17F) in the expression of
pulmonary inflammation (Fig. 1).
CONCLUSION
ML-1 (IL-17F) is expressed in a variety of human tissues
and in activated CD4+ T cells, mast cells, basophils and
PBMC. ML-1 is able to induce several cytokines, chem-
okines and adhesion molecules from various cell types.
While the ML-1 receptor remains unknown, the Raf1-
MEK-ERK1/2 is a central signal pathway of ML-1
(M Kawaguchi et al., unpubl. obs., 2002).18 These data
suggest a potential role for ML-1 (IL-17F) in the patho-
genesis of inflammatory processes, such as COPD,
bronchial asthma and bacterial pneumonia. Further
work is clearly needed to define the role of ML-1
(IL-17F), and analyses of ML-1 (IL-17F) transgenic and/
or deficient mice would provide a crucial step towards
this aim.
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